Trials / Completed
CompletedNCT03603366
Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and Rectum
Patient-centred Benefit-risk Observational Study of Low-dose Aspirin for CVD (Cardiovascular Disease) and CRC (Colorectal Cancer) Prevention
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,028 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Research shows that low-dose Aspirin prevents diseases of heart and blood vessels as well as cancer of the colon and rectum and it is also associated with risk of bleeding. In this study, they want to learn how patients regard the benefits and risks of low-dose Aspirin for the prevention of these diseases. The researchers also want to learn how patients balance these risks and benefits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acetylsalicylic acid (Aspirin, BAYE4465) | This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin. |
Timeline
- Start date
- 2019-08-14
- Primary completion
- 2019-10-14
- Completion
- 2019-10-14
- First posted
- 2018-07-27
- Last updated
- 2020-10-05
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT03603366. Inclusion in this directory is not an endorsement.